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ribosomal peptides from Streptomyces sp.
FXJ1.264†
Ning Liu,‡a Lijiang Song,‡b Minghao Liu,‡ac Fei Shang,d Zoe Anderson,b David J. Fox,b
Gregory L. Challis*b and Ying Huang*a
Streptomycetes are a rich source of bioactive specialized metabolites, including several examples of the
rapidly growing class of ribosomally-biosynthesized and post-translationally-modiﬁed peptide (RiPP)
natural products. Here we report the discovery from Streptomyces sp. FXJ1.264 of azolemycins A–D,
a complex of novel linear azole-containing peptides incorporating a unique oxime functional group.
Bioinformatics analysis of the Streptomyces sp. FXJ1.264 draft genome sequence identiﬁed a cluster of
genes that was hypothesized to be responsible for elaboration of the azolemycins from a ribosomally-
biosynthesized precursor. Inactivation of genes within this cluster abolished azolemycin production,
consistent with this hypothesis. Moreover, mutants lacking the azmE and azmF genes accumulated
azolemycin derivatives lacking the O-methyl groups and an amino group in place of the N-terminal
oxime (as well as proteolysed derivatives), respectively. Thus AzmE, a putative S-adenosyl methionine-
dependent methyl transferase, is responsible for late-stage O-methylation reactions in azolemycin
biosynthesis and AzmF, a putative ﬂavin-dependent monooxygenase, catalyzes oxidation of the
N-terminal amino group in an azolemycin precursor to the corresponding oxime. To the best of our
knowledge, oxime formation is a hitherto unknown posttranslational modiﬁcation in RiPP biosynthesis.Introduction
Despite remarkable advances in the science of chemical
synthesis, bioactive natural products continue to provide useful
starting points for the development of new drugs and agro-
chemicals.1 Many natural products are peptides or peptide
derivatives which can be divided into two major classes, non-
ribosomal peptides (NRPs) and ribosomally-biosynthesized and
post-translationally-modied peptides (RiPPs), based on their
diﬀering biosynthetic origins.2,3 NRPs are assembled by
modular multienzyme assembly lines and are widely used in therces, Institute of Microbiology, Chinese
. China. E-mail: huangy@im.ac.cn; Fax:
wick, Coventry, UK CV4 7AL. E-mail: G.L.
24112; Tel: +44 (0)2476 574024
Beijing, 100049, P. R. China
iversity of Chemical Technology, Beijing
SI) available: Experimental procedures,
the proposed functions of genes within
f which has been deposited in the
e accession no. KT336319. See DOI:
e work.clinic as antibiotics (e.g. vancomycin,4 penicillins/cephalospo-
rins,5 and daptomycin6), immunosuppressants (e.g. cyclo-
sporine7) and anticancer agents (e.g. bleomycin8). The advent of
high throughput genome sequencing in the 21st century
coupled with the development of in silico sequence mining tools
has revealed RiPPs as a second major class of peptide natural
products, endowed with a high degree of structural diversity
and a wide variety of bioactivities.3 In comparison with NRP
biosynthetic gene clusters, those responsible for RiPP biosyn-
thesis are relatively small and are more amenable to genetic
manipulation for the creation of novel derivatives.9–12
Linear azol(in)e-containing peptides (LAPs) typically incor-
porate several (methyl)oxazol(in)es and/or thiazol(in)es and
represent an important family of RiPPs exemplied by microcin
B17 and goadsporin.13,14 The enzymology underlying post-
translational azol(in)e formation has generated considerable
interest in this family of RiPPs over the past two decades.15–17
However, relatively little is known about the biosynthesis of
LAPs in actinobacteria,18 which are considered to be prolic
producers of RiPPs.3
Here we report the discovery of azolemycins A–D, a novel
complex of LAPs containing a unique oxime functional group,
from Streptomyces sp. FXJ1.264. This strain, isolated from red
soil collected in the Jiangxi Province of southeast China, hasThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinealready been shown to produce two known classes of bioactive
polyketide metabolites, the etheromycins and the anthra-
benzoxocinones.19,20 We also report identication of the azole-
mycin biosynthetic gene cluster, and show that genes predicted
to encode a avin-dependent monoxygenase and an S-adenosyl
methionine (SAM)-dependent methyl transferase are respon-
sible for oxime formation and late stage methylation, respec-
tively, in azolemycin biosynthesis.Results and discussion
Isolation and structure elucidation of the azolemycins
UHPLC-MS analysis of ethanol extracts from small-scale cultures
of Streptomyces sp. FXJ1.264 grown on GYM agar identied two
potentially interesting metabolites with m/z ¼ 670.3 and 684.3.
Dried ethanol extracts from large-scale (25 L) agar cultures were
fractionated by silica gel column chromatography eluting with
chloroform/methanol. Fractions containing the metabolites of
interest were combined and subjected to Sephadex LH-20
column chromatography, eluting with methanol, to remove
lipophilic impurities. Separation of the resulting mixture of
metabolites by semi-preparative HPLC yielded one pair of
compounds with the molecular formula C31H39N7O8S and
another pair of compounds with the molecular formula
C32H41N7O8S (see ESI†). Database searches using thesemolecular
formulae showed that the compounds are novel. The puried
isomers were found to readily interconvert upon prolonged
storage, or in acidic solvents such as chloroform.
Using 1- and 2-D NMR spectroscopy, the planar structure was
established for the more abundant lower molecular weight
isomer (Fig. 1 and ESI†). This compound was named azolemy-
cin A. The NMR data for the less abundant lower molecular
weight isomer, azolemycin B, are very similar to those for azo-
lemycin A. The biggest discrepancy is in the chemical shi of
the signal due to the methine proton in the isopropyl group of
the oxime (3.47 for azolemycin A compared with 3.05 for azo-
lemycin B). We thus hypothesized that azolemycins A and B
diﬀer only in the conguration of the oxime. To test this
hypothesis, azolemycins A and B were hydrolyzed under mildly
acidic conditions and the products of the reactions were
analyzed by high resolution UHPLC-MS, which showed they had
identical retention times and molecular formulae, corre-
sponding to the ketone resulting from hydrolytic cleavage of theFig. 1 Key correlations observed in COSY andHMBCNMR spectra of azo
NMR spectroscopy and degradation studies.
This journal is © The Royal Society of Chemistry 2016oxime (see ESI†). To assign the conguration of the oximes in
azolemycin A and B, 1H NMR chemical shis for the E and Z
isomers of the oxime derived from condensation of the N-
methyl amide of a-ketoisovaleric acid with hydroxylamine were
calculated, using methodology recently reported by Tantillo and
coworkers.21 Themethine proton in the model oxime with the E-
conguration was predicted to have a chemical shi of 3.61
ppm, whereas the corresponding proton in the Z-congured
oxime was predicted to have a chemical shi of 3.09 ppm (See
ESI†). Thus the congurations of the oximes in azolemycins A
and B were assigned as E and Z, respectively.
To determine the congurations of the stereogenic centers in
azolemycin A, it was hydrolyzed in strong acid and the valine and
isoleucine produced were derivatized using Marfey's reagent.22
LC-MS comparisons with Marfey's derivatives of L- and D-valine
established the S-conguration for the stereocenter bearing the
isopropyl group. The a-carbon in the isoleucine residue was also
shown to have the S-conguration by comparison with Marfey's
derivatives of L-isoleucine, L-allo-isoleucine, D-isoleucine and D-
allo-isoleucine. However, the conguration of the b-carbon could
not be established on the basis of such comparisons. Thus we
compared the NMR data for the a-proton of the isoleucine
residue with literature values. In CDCl3, the a-proton in the
methyl ester of N-benzoyl-allo-isoleucine is reported to have
a chemical shi of 4.90 ppm and coupling constants of 4.3 and
9.0 Hz, whereas the corresponding proton in the methyl ester of
N-benzyol-isoleucine has a chemical shi of 4.70 ppm and
coupling constants of 5.2 and 8.6 Hz.23 The a-proton of the
isoleucine residue in azolemycin A has a chemical shi of 4.73
ppm and coupling constants of 5.4 and 8.8 Hz (also in CDCl3).
This indicates that the isoleucine residue in azolemycin A does
not possess the allo relative conguration, leading us to assign
the S-conguration to the b-carbon. This assignment was further
conrmed by comparison of the 1H NMR spectra of azolemycin A
with a chemically-synthesized mimic of its 5-aryl-3-methyl-oxa-
zole-2-carboxyl-L-isoleucine methyl ester moiety (see ESI†). Thus
structures 1 and 2 (Fig. 1) were assigned to azolemycins A and B,
respectively. The structure of azolemycin A has been indepen-
dently conrmed by total synthesis, details of which will be re-
ported elsewhere.24
HRMS, NMR data and chemical shi calculations for the
isomeric higher molecular weight azolemycin congeners indi-
cated that they are derivatives of azolemycins A and B in whichlemycin A, and the structures of azolemycins A–D deduced fromHRMS,
Chem. Sci., 2016, 7, 482–488 | 483
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View Article Onlinethe oxime has been O-methylated (see ESI†). These compounds
were named azolemycins C (3) and D (4), respectively (Fig. 1).Identication and characterization of the azolemycin
biosynthetic gene cluster
Inspection of the structure of the azolemycins suggests that they
are elaborated from a peptide with the sequence VVSTCTI.
Genomic DNA was extracted from Streptomyces sp. FXJ1.264 and
subjected to Roche 454 FLX sequencing, resulting in a total of
9 436 877 bp of genome sequence distributed across 254 contigs
($500 bp) with an average size of 37 153 bp. To investigate
whether the peptide precursor of the azolemycins is ribosomally
biosynthesized, the dra genome sequence of Streptomyces sp.
FXJ1.264 was searched for coding sequences (CDSs) corre-
sponding to the putative precursor. This resulted in identica-
tion of a 219 bp CDS, named azmA, which encodes a protein
containing the putative precursor peptide anked by 55 N-
terminal residues and 10 C-terminal residues. Comparative
sequence analyses of the proteins encoded by the CDSs anking
azmA indicated that they are likely involved in maturation of the
putative azolemycin precursor peptide (Fig. 2 and ESI†). The
azmC/D gene encodes a protein with sequence similarity to ATP-
dependent cyclases known to catalyze the conversion of Ser, Thr
and Cys residues to the corresponding azolines in the biosyn-
thesis of other LAPs,16 and azmB encodes a homologue of avin-
dependent dehydrogenases that convert the azolines to the cor-
responding azoles.17 Thus, AzmC/D is proposed to catalyze four
cyclodehydration reactions in AzmA (5) to yield 6, which
undergoes AzmB-catalyzed oxidation to yield 7 (Fig. 2). ProteolyticFig. 2 Organization of the azolemycin biosynthetic gene cluster and
FXJ1.264. It is likely that AzmF produces exclusively the E-oxime and tha
azolemycin A. Azolemycin C and D appear to arise from AzmE-catalysedO
484 | Chem. Sci., 2016, 7, 482–488cleavage of the N-terminal leader peptide and the C-terminal
decapeptide in 7 would yield 8. Interestingly, the protease(s)
responsible for this do not appear to be encoded by genes within
the putative azolemycin biosynthetic gene cluster, as is the case
for other azol(in)e-containing RiPPs produced by Streptomyces
species, such as goadsporin and berninamycin.25,26 The azmE and
azmF genes encode a putative S-adenosyl methionine (SAM)-
dependent methyl transferase and a avin-dependent mono-
oxygenase, respectively. AzmF is predicted to oxidise the valine
amino group in 8 resulting in the corresponding oxime 9 (Fig. 2).
AzmE is hypothesized to catalyze methylation of the isoleucine
carboxyl group in 9 to give azolemycins A and B (1 and 2). AzmE
may also catalyze O-methylation of the oxime group in 1 and 2 to
yield azolemycins C and D (3 and 4). The azmR gene encodes
a putative LysR family transcriptional regulator, and likely plays
a role in the regulation of azolemycin biosynthesis. The CDSs
downstream of azmF and upstream of azmR encode proteins with
no obvious role in azolemycin biosynthesis.
To verify that azmA encodes the azolemycin precursor
peptide, a mutant of Streptomyces sp. FXJ1.264 containing a 180
bp in-frame deletion within this CDS was constructed (see ESI†
for details). UHPLC-HRMS analysis of culture extracts
conrmed that azolemycin production is abolished in this
mutant (Fig. 3). The involvement of azmC/D in azolemycin
biosynthesis was similarly established by creating a mutant of
Streptomyces sp. FXJ1.264 in which this CDS has been replaced
by the neo gene, which confers kanamycin resistance. UHPLC-
HRMS analyses conrmed that culture extracts from this
mutant does not contain azolemycins (Fig. 3).proposed pathway for azolemycin biosynthesis in Streptomyces sp.
t azolemycin B arises from facile isomerization of the oxime group in
-methylation of the oxime group in azolemycins A and B, respectively.
This journal is © The Royal Society of Chemistry 2016
Fig. 3 Extracted ion chromatograms from UPLC-HRMS analyses of culture extracts from wild type Streptomyces sp. FXJ1.264 and its DazmA,
DazmC/D, DazmE and DazmF mutants. The m/z values used to generate each chromatogram are listed on the right.
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View Article OnlineThe proposed role of AzmF in azolemycin biosynthesis, as
a avin-dependent monooxygenase that catalyzes oxidation of
the amino group in 8 to the corresponding oxime, was investi-
gated by constructing a mutant of Streptomyces sp. FXJ1.264 in
which azmF is replaced with the neo gene. UHPLC-HRMS
analysis showed that the production of azolemycins A–D (1–4) isThis journal is © The Royal Society of Chemistry 2016abolished in this mutant. However, three putative azolemycin
derivatives were produced by the mutant (Fig. 3). Comparison of
the MS/MS spectra for these compounds with that for azole-
mycin A (1) showed that they are the proposed biosynthetic
intermediate 8, a derivative 10 missing the N-terminal valine
residue, and a derivative 11 of azolemycins A/B (1 and 2)Chem. Sci., 2016, 7, 482–488 | 485
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View Article Onlinesimilarly lacking the N-terminal residue (Fig. 4 and ESI†). 10
presumably derives from 8 via proteolytic cleavage and 11
probably arises from subsequent AzmE-catalyzed methylation
of 10. These data are consistent with the proposed role of AzmF
in azolemycin biosynthesis and suggest that oxime formation,
which is to the best of our knowledge without precedent as
a posttranslational modication in RiPP biosynthesis, serves to
prevent proteolytic degradation of the azolemycins (Fig. 2). In
contrast to RiPPs, several NRPs containing an oxime group are
known, including nocardicins A and B, caerulomycin A,
althiomycin and collismycin A.21,27–29 The cytochrome P450
NocL and avin-dependent two-component monooxygenase
CrmH are responsible for late-stage oxidation of an amino
group to the corresponding oxime in the biosynthesis of
nocardicin and caerulomycin, respectively,30,31 and in althio-
mycin biosynthesis a putative di-iron-dependent oxygenase has
been proposed to catalyze an analogous transformation.32,33
Finally, in collismycin biosynthesis, the putative avin-depen-
dent monooxygenase ClmM, which shares 46% sequence
identity with AzmF, is implicated in the oxidation of a primary
amine to the corresponding oxime.34
To explore whether AzmF homologues are involved in the
biosynthesis of other LAPs, we queried the “all genomes”
database of the Joint Genome Institute with the sequence of
AzmF. All of the top 20 hits were from actinobacterial genomes
and most of them resided in putative NRP biosynthetic gene
clusters. A single hit was found within a putative LAP biosyn-
thetic gene cluster in the genome of Actinomadura oligospora
ATCC 43269. In addition to azmF, azmC/D and azmB homo-
logues, this gene cluster contained four genes encoding puta-
tive precursor peptides (see ESI†). Experimental analysis of the
metabolic product(s) will be required to establish whether the
AzmF homologue encoded by this gene cluster is responsible
for posttranslational oxime formation or some other type of
oxidative transformation.Fig. 4 Key fragment ions observed in UHPLC-HRMS/MS analyses of azol
intermediate 9 in culture extracts of the azmEmutant, and shunt metabo
the molecular formula of each fragment ion are shown for comparison
486 | Chem. Sci., 2016, 7, 482–488The function of AzmE, which belongs to the same family of
SAM-dependent methyl transferases (COG3315) as the BmbA/
BtmB/BotOMT/BstB enzyme responsible for posttranslational
O-methylation of an aspartate side chain in bottromycin
biosynthesis,10,35–37 was investigated by constructing a mutant of
Streptomyces sp. FXJ1.264 in which azmE is replaced with the neo
gene. UHPLC-HRMS of culture extracts showed that none of the
azolemycins are produced by the mutant, but two compounds
with molecular formulae corresponding to demethylated
derivatives of azolemycin A (1) were identied (Fig. 3).
Comparison of the MS/MS spectra of these compounds with the
corresponding spectrum for azolemycin A indicated that they
are the E- and Z-oxime isomers of proposed intermediate 9 in
azolemycin biosynthesis (Fig. 4). O-Methylation of the carboxyl
terminus is a rare posttranslational modication of RiPPs, but
has recently been reported for several linear cyanobactins
produced by cyanobacteria.38Bioactivity of the azolemycins
The azolemycins were tested for antiproliferative and antimi-
crobial activities (see ESI†). Azolemycin C showed moderate
antiproliferative eﬀects against human colon cancer cell line
HCT116 with an IC50 value of 69.2  3.3 mM, with the positive
control cisplatin showing an IC50 value of 22.7  1.8 mM.
Similarly, azolemycin B displayed modest antiproliferative
activity against human bladder (T24) and cervical (HeLa) cancer
cell lines with IC50 values of 88.4  8.5 and 96.0  3.5 mM,
respectively. In comparison, cisplatin showed IC50 values of 11.5
 0.2 and 3.6  0.2 mM, respectively, against the same cell lines.
Azolemycin D showed weak antiproliferative activity against
HeLa cell lines only, while azolemycin A did not exhibit any
antiproliferative activity against the six cell lines tested (see
ESI†). None of the four compounds showed activity against
Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candidaemycin A (1) in culture extracts of wild type Streptomyces sp. FXJ1.264,
lites 8, 10 and 11 in the azmFmutant. Calculatedm/z values based on
with the measured values (see ESI† for spectra).
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinealbicans or Candida pseudorugosa. These data indicate that the
azolemycins probably do not function as antibiotics in the
natural environment of the producing organism. The ability of
the azolemycins to promote (at low concentrations) or inhibit
(at high concentrations) the growth of other actinobacteria was
also examined, but no activity was observed. Further experi-
ments are required to determine whether the azolemycins
possess other, more potent, biological activities.
Conclusions
Azolemycins A–D, four new LAPs containing a unique oxime
functional group withmodest activity against mammalian cancer
cell lines, have been isolated from Streptomyces sp. FXJ1.261. The
genome of Streptomyces sp. FXJ1.261 has been partially
sequenced, allowing identication of the azmA gene, encoding
a putative azolemycin precursor peptide. In-frame deletion of
azmA abolished production of the azolemycins, as did replace-
ment of the adjacent azmC/D gene, predicted to encode a YcaO
domain-containing azoline synthetase, with a gene conferring
kanamycin resistance. The azmE and azmF genes anking azmA
and azmC/D were predicted to encode a SAM-dependent methyl
transferase and a avin-dependent monoxygenase, respectively.
Based on the azolemycin derivatives observed to accumulate in
an azmFmutant, it was concluded that AzmF catalyzes oxidation
of the amino group in the N-terminal valine residue arising from
cleavage of the 55 amino acid leader peptide in AzmA to the
corresponding oxime. Similarly, analysis of an azmE mutant
showed that AzmE catalyses methylation of the carboxyl group in
the C-terminal isoleucine residue resulting from cleavage of the
C-terminal decapeptide from AzmA. In addition, AzmE appears
to catalyze O-methylation of the oxime group in azolemycin A
and/or B. In common with other LAP biosynthetic gene clusters
in Streptomyces species, the azolemycin biosynthetic gene cluster
lacks genes encoding the proteases needed to cleave the 55
amino acid leader sequence and the C-terminal decapeptide
from the AzmA precursor peptide.
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